VentriJect.
2024/5 | Public Relations
Client
VentriJect is a MedTech spinout from Aalborg University. The company was founded with a mission to revolutionise how cardiorespiratory fitness is measured, using its clinically validated and patented technology, Seismofit® - a unique technology that enables Vo2 max to be estimated accurately, without the need for exercise, and in under three minutes.
Using the Seismofit® system, a person’s cardiorespiratory fitness (quantified as VO2 max) can be estimated in less than 3 minutes and without the need to exercise. This is a revolution in how we estimate cardiorespiratory fitness.
It works using a small sensor on a device that registers movements in the chest caused by the beating heart using a technique called seismocardiography. Utilising this together with the VentriJect algorithm, an accurate reading of VO2 max is delivered via the VentriJect app to the user. Seismofit® is a CE-marked medical device.
VentriJect is growing rapidly and has already gained traction in the UK, Germany and Denmark. The company appointed Tarleton to develop help raise its profile in the UK and Germany following a series of new customer acquisitions.
Challenge
Raise VentriJect’s profile within the MedTech, fitness and preventative health sectors to increase consideration amongst key target audiences; and to strengthening its positioning as an innovative company focused on supporting preventative healthcare.
Solution
We worked closely with the VentriJect team to identify media opportunities and plan out a 12-month campaign targeting MedTech, fitness and preventative health audiences.
Drawing on our extensive MedTech experience, and our expertise in profile raising, we drafted press releases that aligned VentriJect’s announcements with the current news agenda to secure top tier coverage in DigitalHealth, MedTech Innovation News, Compsmag, the Clinical Services Journal and more.
We identified feature opportunities for VentriJect to reach specialist audiences across the fitness and wellness sectors and drafted an extensive product feature that was featured in the leading technology publication, T3.
As Seismofit has both medical technology and consumer applications, we leveraged our strong broadcast relationships to secure VentriJect a slot on BBC Click, the BBC’s flagship technology programme in the UK and worldwide, with a reach of over 100 million people. The presenter tested Seismofit and explored its benefits with VentriJect’s CEO, Mikkel Kristiansen. This was aired on BBC One, BBC News and the BBC World Service.
You can watch the full report here.
Mikkel Kristiansen
CEO, VentriJect
